Kristen A. Rodrigues

Featured in: Favicon

nature.com Favicon

cell.com

biorxiv.org

Articles

Diverse priming outcomes under conditions of very rare precursor B cells

Nov 22, 2024 | biorxiv.org | Patrick Madden |Ester Marina-Zárate |Kristen A. Rodrigues |Jon M. Steichen

AbstractRare B cells can have special pathogen-recognition features giving them the potential to make outsized contributions to protective immunity. However, rare naive B cells infrequently participate in immune responses. We investigated how germline-targeting vaccine antigen delivery and adjuvant selection affect priming of exceptionally rare BG18-like HIV broadly neutralizing antibody-precursor B cells (~1 in 50 million) in non-human primates.
Vaccines combining slow delivery and follicle targeting of antigens increase germinal center B cell clonal diversity and clonal expansion

Aug 19, 2024 | biorxiv.org | Kristen A. Rodrigues |Yiming Zhang |Aereas Aung |Duncan M. Morgan

AbstractVaccines incorporating slow delivery, multivalent antigen display, or immunomodulation through adjuvants have an important role to play in shaping the humoral immune response.
A combined adjuvant approach primes robust germinal center responses and humoral immunity in non-human primates - Nature Communications

Nov 4, 2023 | nature.com | Ivy Phung |Kristen A. Rodrigues |Ester Marina-Zárate |Bapi Pahar |Wen-Hsin Lee |Pyone P. Aye | +13 more

AbstractAdjuvants and antigen delivery kinetics can profoundly influence B cell responses and should be critically considered in rational vaccine design, particularly for difficult neutralizing antibody targets such as human immunodeficiency virus (HIV). Antigen kinetics can change depending on the delivery method.
Optimization of an alum-anchored clinical HIV vaccine candidate - npj Vaccines

Aug 12, 2023 | nature.com | Kristen A. Rodrigues |Chris Cottrell |Yash Agarwal |William R. Schief

AbstractIn the ongoing effort to develop a vaccine against HIV, vaccine approaches that promote strong germinal center (GC) responses may be critical to enable the selection and affinity maturation of rare B cell clones capable of evolving to produce broadly neutralizing antibodies.